Human Immunodeficiency Virus (HIV) Infection Clinical Trial
Official title:
A Multiple-Dose Clinical Trial to Study the Effect of MK-1439 (Doravirine) on Methadone Pharmacokinetics
This study will evaluate the effects of multiple doses of doravirine (MK-1439) on the pharmacokinetics of methadone in participants requiring methadone maintenance therapy. The primary hypothesis is that area under the plasma concentration-time curve to 24 hours postdose (AUC0-24) of (R)-methadone is similar when a maintenance regimen of methadone is administered with or without multiple daily doses of doravirine.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03667547 -
Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)
|
Phase 4 | |
| Completed |
NCT01422330 -
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
|
Phase 4 | |
| Active, not recruiting |
NCT05452616 -
Same-day Versus Rapid ART Initiation in HIV-positive Individuals Presenting With Symptoms of Tuberculosis
|
N/A | |
| Completed |
NCT04515641 -
Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)
|
Phase 1 | |
| Not yet recruiting |
NCT06430905 -
Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART
|
Phase 1 | |
| Terminated |
NCT02818283 -
Soy Modulation of Immune Activation, LDL- Levels, and Lowering Inflammation by Pretzel Isoflavone Dietary Intervention
|
N/A | |
| Completed |
NCT04303156 -
Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)
|
Phase 1 | |
| Completed |
NCT00717067 -
Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function
|
Phase 4 | |
| Recruiting |
NCT04375800 -
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Ages 4 Weeks to <12 Years and <45 kg (MK-1439-066)
|
Phase 2 | |
| Completed |
NCT00821535 -
Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers
|
Phase 1 | |
| Completed |
NCT03618511 -
Interventions to Improve HIV Antiretroviral Therapy Adherence
|
N/A | |
| Completed |
NCT01768182 -
Folinic Acid and Vascular Reactivity in HIV
|
N/A |